Compounds may help treat certain neurological disorders
August 5, 2025
Compounds may help treat certain neurological disorders
At a Glance
- An experimental small molecule alleviated CoQ10 deficiency and reversed associated brain damage in a boy with a rare disease.
- The results suggest a practical approach to treating inherited diseases involving reduced CoQ10 levels.
Human cells gain their energy by breaking down compounds from food, mainly sugars and fats. This process takes place in cellular compartments called mitochondria. A molecule called coenzyme Q10 (CoQ10) plays a key role in this process. Low CoQ10 levels, caused by an inability to make CoQ10, are associated with diseases called primary CoQ10 deficiencies. Many of these diseases have neurological symptoms. Boosting CoQ10 levels might help treat these diseases. But while dietary supplements with CoQ10 are available, CoQ10 can鈥檛 easily enter the brain.
An alternative way to boost CoQ10 levels would be to use precursor compounds that the body can use to make its own CoQ10. A research team led by Dr. Michael Pacold at NYU Grossman School of Medicine recently figured out the pathway by which the body makes a major part of the CoQ10 molecule called the headgroup. The immediate precursor to the CoQ10 headgroup is a compound called 4-hydroxybenzoate (4-HB). 4-HB, in turn, is made from another compound called 4-hydroxymandelate (4-HMA).
In their new study, which was funded in part by 精东影业, the team tested whether supplementing with 4-HMA or 4-HB could treat diseases caused by CoQ10 deficiencies. Results appeared in Nature on July 9, 2025.
The team first used mice engineered to lack the enzyme that makes 4-HMA, called HPDL. Problems with this enzyme underlie an ultra-rare, lethal neurodevelopmental disorder in people. Normally, mice lacking HPDL die within the first 15 days of life. Oral supplementation with CoQ10 or related compounds did not improve survival. But nearly all the mice supplemented with 4-HMA or 4-HB starting in the first week of life survived for a typical mouse lifespan of 18 months or longer. Treatment with 4-HMA partially reversed problems normally seen in these mice, which include abnormally small mitochondria and abnormal tissue development in the cerebellum, a part of the brain that controls movement.
The researchers used a technique called isotopic labeling to track 4-HMA and 4-HB in the mice. They found that more than half of the mouse equivalent of CoQ10 came from the 4-HMA or 4-HB supplements. This indicated that the supplements were being used to make CoQ10.
Because of these and other encouraging studies in animal models, the team tried using 4-HB to treat an 8-year-old boy with fast-progressing paralysis due to excess muscle contraction. The boy had gone in a span of three months from being able to run and play sports to needing a wheelchair. Genetic testing confirmed that he had disease-causing mutations in the gene for HPDL. The researchers gave the boy 4-HB dissolved in water daily at a high dose for the first month and at reduced doses thereafter.
Within the first two weeks of treatment, various measures of motor function improved. They remained stable or continued to improve over eight total months of treatment. The boy went from falling multiple times a day to falling less than once a week. He was able to run after about a month and a half, and able to ride a bicycle after four months.
The findings suggest that supplementing with CoQ10 precursors can boost CoQ10 levels in mice and humans. This, in turn, can improve the neurological symptoms of CoQ10 deficiency.
鈥淭o our knowledge, this is the first demonstration that neurological symptoms of a primary CoQ10 deficiency can be stabilized or improved by supplying not CoQ10 itself, but instead its smaller, more easily processed precursors,鈥 Pacold says.
鈥攂y Brian Doctrow, Ph.D.
Related Links
- Obesity disrupts mitochondria, reduces fat-burning
- A potential blood test for Parkinson's disease
- Protein may be linked to exercise intolerance in ME/CFS
- SARS-CoV-2 can cause lasting damage to cells' energy production
- Cancer cells drain energy from immune cells
- Mitochondrial DNA involved in sickle cell disease
- Spinal nerve healing enhanced by boost in cellular energy
References
Shi G, Miller C, Kuno S, Rey Hipolito AG, El Nagar S, Riboldi GM, Korn M, Tran WC, Wang Z, Ficaro L, Lin T, Spillier Q, Gamallo-Lana B, Jones DR, Snuderl M, Song SC, Mar AC, Joyner AL, Sillitoe RV, Banh RS, Pacold ME. Nature. 2025 Jul 9. doi: 10.1038/s41586-025-09246-x. Online ahead of print. PMID: 40634618.
Funding
精东影业鈥檚 National Institute of General Medical Sciences (NIGMS), National Cancer Institute (NCI), National Institute of Mental Health (NIMH), National Institute of Neurological Disorders and Stroke (NINDS), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Center for Advancing Translational Sciences (NCATS), and National Institute of Allergy and Infectious Diseases (NIAID); Damon Runyon Cancer Research Foundation; Pershing Square Foundation; Tara Miller Melanoma Foundation; Harry J Lloyd Charitable Trust; Irma T. Hirschl Charitable Trust; Concern Foundation; Harrington Discovery Institute; Oxford-Harrington Rare Disease Centre; NYU Langone Health Technology Opportunities and Ventures; Cycle for Survival; Francois Wallace Monahan Fund; Takeda Science Foundation; Astellas Foundation for Research on Metabolic Disorders; Mochida Memorial Foundation for Medical and Pharmaceutical Research.